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Objectives:  To  determine  whether  the  probability  of  having  heard  about  human  papillomavirus  (HPV)
vaccination  differs  by socio-demographic  characteristics  among  Colombian  women;  and  whether  the
effect of  predictors  of having  heard  about  HPV  vaccination  varies  by  educational  levels  and  rural/urban
area  of  residence.
Methods:  Data of  53,521  women  aged  13–49  years  were  drawn  from  the  2010  Colombian  National  Demo-
graphic  and  Health  Survey.  Women  were  asked  about  aspects  of their  health  and  their  socio-demographic
characteristics.  A  logistic  regression  model  was  used  to  identify  factors  associated  with  having  heard
about  HPV  vaccination.  Educational  level  and  rural/urban  area  of residence  of  the  women  were  tested  as
modiﬁer  effects  of predictors.
Results:  26.8%  of the  women  had  heard  about  HPV  vaccination.  The  odds  of  having  heard  about  HPV vac-
cination  were  lower  among  women:  in  low  wealth  quintiles,  without  health  insurance,  with  subsidized
health  insurance,  and  those  who  had  children  (p <  0.001).  Although  women  in older  age  groups  and  with
better  education  had  higher  probabilities  of  having  heard  about  HPV  vaccination,  differences  in these
probabilities  by age  group  were  more  evident  among  educated  women  compared  to non-educated  ones.
Probability  gaps  between  non-educated  and  highly  educated  women  were  wider  in the  Eastern  region.
Living  in  rural  areas  decreased  the  probability  of  having  heard  about  HPV  vaccination,  although  narrower
rural/urban  gaps  were  observed  in the Atlantic  and  Amazon-Orinoquía  regions.
Conclusions:  Almost  three  quarters  of the  Colombian  women  had  not  heard  about  HPV vaccination,  with
variations  by  socio-demographic  characteristics.  Women  in disadvantaged  groups  were  less  likely  to
have heard  about  HPV  vaccination.
© 2014  SESPAS.  Published  by  Elsevier  España,  S.L.U.  All  rights  reserved.
Factores  que  predicen  haber  oído  sobre  la  vacunación  contra  el  virus  del
papiloma  humano:  aspectos  críticos  para  la  prevención  del  cáncer  de  cuello
uterino  en  mujeres  colombianas
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Objetivos:  Determinar  si la  probabilidad  de  haber  oído  sobre  la  vacunación  contra  el virus  del  papiloma
humano  (VPH)  varía  según  características  socio-demográﬁcas  de  las  mujeres  colombianas;  y  si  el efecto
de estos  predictores  varía  según  nivel  de educación  y el  área  rural/urbana  de  residencia.
Métodos:  Datos  de 53.521  mujeres  entre  13  y 49  an˜os  fueron  extraídos  de  la  Encuesta  Nacional  de
Demografía  y  Salud  de  Colombia,  2010.  Se preguntó  a las mujeres  acerca de  su  salud  y sus  características
socio-demográﬁcas.  Se  utilizó  un  modelo  de  regresión  logística  para  identiﬁcar  los factores  asociados  con
haber  oído  sobre  la  vacunación  contra  el VPH.  Se  evaluó  si  el nivel  educativo  y  el  área  rural/urbana  de
residencia  interactuaban  con  los  predictores.
Resultados:  26,8%  de  las  mujeres  había  oído  sobre  la  vacunación  contra  el VPH.  Las probabilidades  de  haber
oído sobre  la  vacunación  contra  el  VPH  fueron  más  bajas  en  las  mujeres  de quintiles  de riqueza  bajos,
sin  seguro  de  salud,  con  seguro  de  salud  subsidiado,  y  en  aquéllas  que  tenían  hijos  (p  < 0,001).  A  pesar  de
 y con  mejor  educación  tenían  una  mayor  probabilidad  de  haber  oído  sobre  laque las  mujeres  mayores
vacunación  contra  el  VPH,  las diferencias  en  las  probabilidades  por  grupos  de  edad  fueron  más  evidentes
entre  las  mujeres  con  educación  comparadas  con  aquéllas  sin educación.  Las brechas  en  las  probabilidades
entre  las  mujeres  sin educación  y las  altamente  educadas  fueron  mayores  en  la  región  Oriental.  Vivir  en
zonas rurales  disminuyó  la  probabilidad  de  haber  oído  sobre  la vacunación  contra  el VPH, aunque  las
diferencias  rural/urbana  fueron  menos  amplias  en  las regiones  Atlántica  y de  la  Amazonía-Orinoquía.
∗ Corresponding author.
E-mail address: silvia.bermedo@usask.ca (S. Bermedo-Carrasco).
http://dx.doi.org/10.1016/j.gaceta.2014.09.005
213-9111/© 2014 SESPAS. Published by Elsevier España, S.L.U. All rights reserved.
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Conclusiones:  Casi tres  cuartas  partes  de las  mujeres  colombianas  no  habían  oído  sobre  la  vacunación
contra  el  VPH,  con  variaciones  según  sus  características  socio-demográﬁcas.  Las  mujeres  de  grupos  des-
favorecidos  tenían  menos  probabilidades  de  haber  oído  acerca  de  la  vacunación  contra  el  VPH.
©  2014  SESPAS.  Publicado  por  Elsevier  España,  S.L.U.  Todos  los derechos  reservados.
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Cervical cancer (CC) is responsible for over 275,000 female
eaths each year, with more than 500,000 new cases diagnosed
orldwide.1 Persistent infection of the anogenital tract with high-
isk human papillomavirus (HPV), which is a sexually transmitted
isease,2 has been established as a necessary cause for cervical
ntraepithelial neoplasia and cervical cancer.3,4 Factors such as
eing sexually active, young age, oral contraceptive use, socio-
conomic status, high parity, smoking status, and previous HPV
nfections, among others have been associated with the transmis-
ion of HPV.2
Vaccination against certain high-risk HPV types among women
ithout previous exposure to these viruses and ideally before
heir sexual debut has been associated with a reduction of pre-
nvasive cervical lesions.2,5 HPV vaccination provides a potential
ost-effective way to prevent CC.6 Currently, two vaccines are avail-
ble against HPV: the bivalent vaccine protects against HPV types
6 and 18; the quadrivalent one protects against HPV types 6, 11,
6, and 18.5 Awareness of prevention of CC is key to support HPV
accination7 and raising knowledge about the role of HPV in the
evelopment of CC is central improve in CC prevention.8 Previ-
us studies have shown that a lower intention of HPV vaccination
s associated with limited awareness and poor knowledge of HPV
accination.7,9,10 Therefore, measuring awareness of HPV vaccina-
ion is critical for CC prevention programs.
In Colombia, CC is the cancer most frequently affecting
omen.11,12 It has been estimated that about 15% of Colombian
omen will develop a HPV infection during their lifetime.12 The
olombian Instituto Nacional de Vigilancia de Medicamentos y Ali-
entos (INVIMA) approved the quadrivalent and bivalent HPV
accines in 2006 and 2007, respectively;13 then, the HPV vaccines
ere available for women who were willing to pay for them. The
uadrivalent HPV vaccine is an insured service for girls aged 9
ears and older since 2012.14 However, a lack of knowledge about
PV infection and HPV vaccination has been reported in Colombia,
specially among less educated and low income groups.8,15 Indeed,
hese disadvantaged groups have been highly affected by the struc-
ure of the Colombian Sistema General de Seguridad Social en Salud
SGSSS), which is an insurance-based health care system.16 This
ystem has increased barriers to access health care16 and obtain
qual health beneﬁts for individuals unable to pay (subsidized
ealth insurance)16,17 compared to those who can contribute to the
ystem (contributory health insurance)16,18 and those who  belong
o groups with special health care plans (public teachers, workers
f public universities, military forces, police, and employees of the
olombian Oil Company).19
To the best of our knowledge, there are no nationwide studies
n Colombia evaluating socioeconomic and personal factors asso-
iated with having heard about HPV vaccination among women.
herefore, our objectives were to determine: (1) the prevalence
f Colombian women having heard about HPV vaccination; (2)
hether the probability of having heard about HPV vaccination
iffers by age group, educational level, socioeconomic (wealth
uintile) and working status, type of health insurance, region and
ural/urban area of residence, women having experienced inter-
ourse, type of contraceptive method used, and women who have
ad children; and (3) whether the effect of predictors for havingheard about HPV vaccination differs at different educational levels
and rural/urban area of residence.
Methods
The data were drawn from the 2010 National Demographic and
Health Survey (NDHS), a national representative survey conducted
among women  between 13 and 49 years old living in Colombia.
In total, 53,521 out of 56,886 women  participated in the NDHS
(response rate = 94%).20 This survey evaluated socio-demographic
characteristics of participants, as well as different aspects of their
health.
All women  were asked whether they had heard about the HPV
and also if they had ever heard about a vaccine to prevent CC.
Women  who reported having heard about HPV and having heard
about a vaccine to prevent CC were classiﬁed as “1 = have heard
about HPV vaccination;” otherwise, they were classiﬁed as “0 = have
not heard about HPV vaccination.” This was the dependent vari-
able of our study. Self-reported factors considered as independent
variables in the study were age group, educational level, wealth
quintile, working status, type of health insurance, having expe-
rienced intercourse, type of contraceptive method used, having
children, and region and rural/urban area of residence. Atlantic,
Amazon-Orinoquía, Central, Eastern, and Paciﬁc were the regions
established in the Colombian NHDS; Bogotá (the capital) was
included in the Eastern region. Chi-square tests were performed to
test differences in the distribution of women  in different categories
of the independent variables.
A logistic regression model was  built using the manual back-
ward method at a 5% level of signiﬁcance. Variables not included
in the model were tested as confounders; the presence of con-
founding was considered if these variables changed the parameter
estimates of predictors in the model by more than 10%. Addition-
ally, educational level and rural/urban area of residence were tested
as modiﬁer effects.
Unadjusted (UORs) and adjusted odds ratios (AORs), 95% conﬁ-
dence intervals (95% CIs), and p-values were computed. Women
with missing data were excluded from the multivariable analy-
sis. Model diagnostics were examined through receiver-operating
characteristic (ROC) curves and assessment of residuals. The anal-
yses were performed using SAS software version 9.3 (SAS Institute
Inc., Cary, NC, USA).
The Ethical Committee of the Asociación Probienestar de la
Familia Colombiana (Profamilia) provided ethical approval for the
2010 NDHS; participants gave their consent before the administra-
tion of the survey. To use the 2010 NDHS data for the present study,
the University of Saskatchewan Research Ethics Board provided an
exception for ethics review.
Results
In total, data from 53,521 women aged 13–49 years were
obtained. The mean age of the women was 29.2 years (SD = 10.8).
The distribution of women’s characteristics is presented in Table 1.
Of the total women, 14,363 (26.8%, 95% CI 26.3–27.1%) reported
having heard about HPV vaccination. The proportion of women
who heard about HPV vaccination by age group was: 13–18 years,
12.9% (95% CI 11.4–14.4%); 19–24 years, 16.6% (95% CI 15.1–18.1%);
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Table  1
Descriptive statistics for variables used in the model building, unadjusted odds ratios (UOR) and corresponding 95% conﬁdence intervals (CI). National Demographic and
Health Survey (NDHS), Colombia, 2010 (n = 53,521).
Variable Categories All womena Have heard about human
papillomavirus vaccinationa,b
UOR (95% CI)
No (39,158) Yes (14,363)
Age group 41–49 years old 10,736 (20.1) 7164 (18.3) 3572 (24.9) 2.61 (2.45–2.79)
33–40  years old 10,207 (19.1) 7089 (18.1) 3118 (21.7) 2.31 (2.16–2.46)
25–32 years old 11,513 (21.5) 8075 (20.6) 3438 (23.9) 2.23 (2.10–2.38)
19–24 years old 9508 (17.7) 7124 (18.2) 2384 (16.6) 1.76 (1.64–1.88)
13–18 years old 11,557 (21.6) 9706 (24.8) 1851 (12.9) 1
Educational level None 1145 (2.1) 997 (2.6) 148 (1.0) 0.15 (0.13–0.18)
Primary 13,550 (25.3) 11,524 (29.4) 2026 (14.1) 0.18 (0.17–0.19)
Secondary 28,393 (53.1) 21,357 (54.5) 7036 (49.0) 0.34 (0.32–0.35)
Higher 10,433 (19.5) 5280 (13.5) 5153 (35.9) 1
Wealth  quintile Lowest 13,203 (24.7) 11,507 (29.4) 1696 (11.8) 0.15 (0.14–0.17)
Lower 13,642 (25.5) 10,608 (27.1) 3034 (21.2) 0.30 (0.28–0.32)
Middle 11,001 (20.6) 7908 (20.2) 3093 (21.5) 0.41 (0.38–0.43)
Higher 8662 (16.2) 5554 (14.2) 3108 (21.6) 0.58 (0.55–0.62)
Highest 7013 (13.1) 3581 (9.2) 3432 (23.9) 1
Working status No 12,061 (22.5) 9729 (24.8) 2332 (16.2) 0.59 (0.56–0.62)
Yes  41,460 (77.5) 29,429 (75.2) 12,031 (83.8) 1
Type  of health insurance Non-afﬁliated 6180 (11.5) 4739 (12.1) 1441 (10.0) 0.44 (0.42–0.48)
Subsidized 27,970 (52.3) 22,864 (58.4) 5106 (35.6) 0.33 (0.31–0.34)
Special 1454 (2.7) 917 (2.3) 537 (3.7) 0.86 (0.77–0.96)
Contributory 17,917 (33.5) 10,638 (27.2) 7279 (50.7) 1
Area  of residence Rural 14,636 (27.3) 12,366 (31.6) 2270 (15.8) 0.41 (0.39–0.43)
Urban 38,885 (72.7) 26,792 (68.4) 12,093 (84.2) 1
Region  Atlantic 11,474 (21.4) 8322 (21.3) 3152 (21.9) 0.79 (0.74–0.83)
Amazon-Orinoquía 9117 (17.0) 7826 (20.0) 1291 (9.0) 0.34 (0.32–0.37)
Central 13,096 (24.5) 9197 (23.5) 3899 (27.1) 0.88 (0.83–0.93)
Paciﬁc 7737 (14.5) 5651 (14.4) 2086 (14.5) 0.77 (0.72–0.82)
Eastern 12,097 (22.6) 8162 (20.8) 3935 (27.4) 1
Had  experienced intercourse Yes 44,249 (82.7) 31,607 (80.7) 12,642 (88.0) 1.76 (1.66–1.86)
No  9272 (17.3) 7551 (19.3) 1721 (12.0) 1
Contraceptive method Condoms 3633 (6.8) 2440 (6.2) 1193 (8.3) 1.60 (1.48–1.73)
Hormonal methods 8866 (16.6) 6305 (16.1) 2561 (17.8) 1.33 (1.26–1.40)
Female sterilization 11,790 (22.0) 8330 (21.3) 3460 (24.1) 1.36 (1.29–1.43)
Other methods 5491 (10.3) 3898 (10.0) 1593 (11.1) 1.34 (1.25–1.43)
Not  using 23,741 (44.4) 18,185 (46.4) 5556 (38.7) 1
Have  had children Yes 35,126 (65.6) 25,439 (65.0) 9687 (67.4) 1.12 (1.07–1.16)
4.4) 13,719 (35.0) 4676 (32.6) 1
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Table 2
Adjusted odds ratio (AORs) and corresponding 95% conﬁdence intervals (CI) of hav-
ing heard about human papillomavirus vaccination by non-interacting predictors
(n  = 53,520). National Demographic and Health Survey (NDHS) Colombia, 2010.
Predictor Categories AOR  (95% CI)
Wealth quintile Lowest 0.44 (0.40–0.49)
Lower 0.57 (0.53–0.61)
Middle 0.64 (0.59–0.68)
Higher 0.74 (0.69–0.79)
Highest 1
Working No 1.05 (0.98–1.12)
Yes 1
Type of health insurance Non-afﬁliated 0.73 (0.68–0.79)
Subsidized 0.69 (0.66–0.73)
Special 0.91 (0.81–1.02)
Contributory 1
Contraceptive method Condoms 1.19 (1.10–1.29)
Hormonal methods 1.20 (1.13–1.28)
Female sterilization 1.10 (1.03–1.17)
Other methods 1.05 (0.97–1.13)No  18,395 (3
a n (%).
b Some percentages with rounding error.
5–32 years, 23.9% (95% CI 22.5–25.3%); 33–40 years, 21.7% (95% CI
0.3–23.1%); and 41–49 years, 24.9% (95% CI 23.5–26.3%). Among
he 14,363 women who have heard about HPV vaccination, 49% had
econdary education, 23.9% belonged to the highest wealth quin-
ile, 83.8% were working, 50.7% had contributory health insurance,
4.2% were living in urban areas, 27.4% lived in the Eastern region,
8% had experienced intercourse, 38.7% were not using contra-
eptive methods, and 67.4% had children. Statistically signiﬁcant
ifferences were found when comparing socio-demographic and
exual factors among women who had heard about HPV vaccination
nd those who had not. Bivariate analyses indicated that all the pre-
ictors were signiﬁcantly associated with the dependent variable
p-values < 0.001); UORs and their 95% CI are shown in Table 1.
In the model building, age was found to be not linearly related to
he log odds of the outcome (p < 0.001); therefore, it was  included
s a ﬁve-category variable which was created according to age
istribution. Working status and having experienced intercourse
ere variables initially removed from the model (p-values > 0.05);
otwithstanding, working status was found to be a confounding
ariable and was included as a covariate in the model. Also, sig-
iﬁcant interactions were found between educational level and
ge group (p = 0.002), educational level and region (p < 0.001), and
ural/urban area of residence and region (p < 0.001).Table 2 presents AORs and their corresponding 95% CIs of pre-
ictors not interacting in the logistic regression model. Regarding
ealth quintile, women in the lowest (AOR = 0.44, 95% CI 0.40–0.49)
nd lower (AOR = 0.57, 95% CI 0.53–0.61) quintiles were less likelyNot using 1
Have had children Yes 0.87 (0.81–0.92)
No 1
to have heard about HPV vaccination in comparison to women from
the highest quintile. Similarly, women  in the middle (AOR = 0.64,
95% CI 0.59–0.68) and higher (AOR = 0.74, 95% CI 0.69–0.79) wealth
quintiles were less likely to have heard about HPV vaccination.
The type of health insurance was also signiﬁcantly associated
with having heard about HPV vaccination. Women  with subsidized
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lityig. 1. Predicted probabilities and 95% CIs of having heard about HPV vaccination
y  age group and educational level; NDHS Colombia, 2010.
ealth insurance (AOR = 0.69, 95% CI 0.66–0.73) and those non-
fﬁliated to any health insurance (AOR = 0.73, 95% CI 0.68–0.79)
ere less likely to have heard about HPV vaccination than women
n the contributory group. Women  using condoms (AOR = 1.19, 95%
I 1.10–1.29), hormonal methods (AOR = 1.20, 95% CI 1.13–1.28), or
ho were sterilized (AOR = 1.10, 95% CI 1.03–1.17) were more likely
o have heard about HPV vaccination than those not using any con-
raceptive method. Furthermore, women with children were less
ikely to have heard about HPV vaccination compared to women
ith no children (AOR = 0.87, 95% CI 0.81–0.92).
Predictors interacting in the model are depicted in Figs. 1–3.
he probabilities of having heard about HPV vaccination were
igher among older age groups and women with better levels of
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ig. 2. Predicted probabilities and 95% CIs of having heard about HPV vaccination
y  region of residence and educational level; NDHS Colombia, 2010.Fig. 3. Predicted probabilities and 95% CIs of having heard about HPV vaccination
by  region and rural/urban area of residence; NDHS Colombia, 2010.
education; however, differences in these probabilities by age group
were more evident among educated women compared to non-
educated ones (Fig. 1). Comparing the level of education by region
(Fig. 2), it was  observed that women  with no education had the
lowest probabilities of having heard about HPV vaccination in all
regions, and that the probability gap between these women and the
highly educated ones was wider in the Eastern than in the Amazon-
Orinoquía region. Also, among women  with high educational levels,
those living in the Amazon-Orinoquía region had the lowest prob-
ability of having heard about HPV vaccination; however, highly
educated women of the Amazon-Orinoquía region were more likely
to have heard about vaccination than those with lower levels of
education in any other region. Furthermore, women living in rural
areas had lower probabilities of having heard about HPV than those
living in urban areas (Fig. 3); notwithstanding, women  living in
urban areas of the Amazon-Orinoquía region had similar probabil-
ities than those living in rural areas of the Eastern region. Also,
narrower gaps between women in rural and urban areas were
observed in the Atlantic and Amazon-Orinoquía regions.
In the model diagnostics, the ROC curve showed that the logis-
tic model correctly classiﬁed 72.5% of the women who had heard
about HPV vaccination, which could be considered as satisfactory.
Also, the assessment of residuals showed that they were within an
adequate range of ±3 standard deviations from zero.
Discussion
The low prevalence of women  who had heard about HPV vacci-
nation found in our results is in accordance with a previous study
claiming a poor awareness of HPV vaccination among adolescents
in Cartagena, Colombia.21 This lack of awareness of HPV vaccination
in the country could be resulting from poor national “HPV educa-
tional efforts”.8 Other authors in Colombia have reported a higher
proportion of individuals aware of HPV and HPV vaccination;8,15
however, their samples included patients attending health care
centers. The participants of these studies could have more access
to HPV-related information which could increase their level of HPV
awareness. Also, these studies did not include women below 18
years and data were drawn from larger cities, such as Medellín8
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nd Bogotá.15 Our study included not only nationwide data of
omen aged 18–49 years but also incorporated data of women
rom 13 to 17 years which represented 18.2% of the total sample.
e  identiﬁed that women in the youngest age group had the lowest
revalence of having heard about HPV vaccination. Studies in other
ountries have reported higher awareness of HPV vaccination.22,23
 recent study in developed countries identiﬁed that more than 80%
f women had heard about HPV vaccination;23 in contrast, after a
ass media advertisement campaign to promote HPV vaccination
n Argentina, 36% of the women had an adequate knowledge about
PV vaccination.22
Different studies have considered the existence of vari-
tions in the level of awareness of HPV vaccination by
ocioeconomic8,15,21–25 and educational status.7–10,15,22,24,25 We
dentiﬁed that the prevalence of having heard about HPV vaccina-
ion was low among women who belonged to deprived socioeco-
omic levels, non-insured individuals, and women covered by the
ubsidized health insurance. These ﬁndings are in agreement with
ther studies showing socioeconomic disparities in knowledge of
PV vaccination in Colombia.8,15,21 A study conducted among indi-
iduals with genital warts in Bogotá identiﬁed that participants
ithout health insurance coverage, and beneﬁciaries of the sub-
idized health insurance were less aware of HPV vaccination.15 In
act, individuals in the subsidized health insurance receive about
0% less health beneﬁts than those in the contributory one,18
nd most of the non-insured people belong to the lowest income
roup.17 Therefore, barriers to access health care experienced by
isadvantaged groups in Colombia could be affecting knowledge
bout HPV and HPV vaccination, since health care professionals are
n important source of information about HPV vaccination and a
otivating factor for HPV vaccine intake.9,10,22,24,26
Our results show novel information regarding modiﬁer effects of
ducation and rural/urban residence on the awareness of HPV vac-
ination. In Colombia, researchers have identiﬁed that individuals
iving in rural areas are more likely to report a poor health status,27
nd that these individuals are highly impacted by economic, polit-
cal, and social problems of the country compared to people living
n urban areas.28 Furthermore, low educational levels and high
overty indicators have been reported in departments located in
he Amazon-Orinoquía, Paciﬁc, and Atlantic regions.29 These ﬁnd-
ngs agree with our results that show low probabilities of having
eard about HPV vaccination among women living in these three
egions of Colombia, speciﬁcally if they have rural residence and
ow educational levels. Thus, there is a need to reduce these gaps
hen designing and implementing educational initiatives about
PV vaccination. Further programs educating the general popu-
ation about CC and its relation to HPV are critical to increase
nowledge about HPV vaccination.8,9,15,30
Although it is known the role that parents have in approving par-
icipation of their daughters in HPV vaccination programs,7,9,25,31,32
e identiﬁed that women with children were less likely to have
eard about HPV vaccination compared to women with no children,
djusting by age and other factors. This lack of awareness suggests
hat parents could be experiencing limitations to obtain informa-
ion about HPV vaccination. A qualitative study conducted in four
olombian regions showed that parents were unaware of HPV
accination and that receiving information was central to decide
accinating their daughters.31 Additionally, it needs to be recog-
ized that the socioeconomic context of parents impacts on their
bility to support HPV vaccination of their family members.25,31
iven that discussions about HPV vaccination between parents and
hildren are a starting point to approach sexuality issues,31,32 con-
inuous efforts to educate about CC prevention and HPV vaccination
re deﬁnitely needed not only for young women10,30 but also for
lder populations (i.e. parents and grandparents). Women  needanit. 2015;29(2):112–117
multiple sources of information about HPV vaccination, including
the advice that they could receive from other women they trust.30
We  propose that CC prevention and education programs recog-
nize and overcome existing inequities – “inequalities considered
unfair or stemming from some form of injustice”33 – in the aware-
ness of HPV vaccination. Therefore, national and local campaigns
should be encouraged to change the paradigm of insufﬁcient
commitment to improve prevention and health promotion pro-
grams within the Colombian SGSSS.19 These campaigns should
ensure the reception of educational messages about HPV vaccina-
tion in the general population, emphasizing socially disadvantaged
groups.22,24,25 Furthermore, working with health care profession-
als, schools, and community organizations might help develop
better health promotion and preventive strategies to overcome dif-
ﬁculties related to area and region of residence, educational level,
and health insurance coverage. We  also recommend studies that
evaluate successful experiences about HPV vaccination awareness
and CC prevention campaigns to adjust and replicate them across
the country. These studies should also include an assessment of
the knowledge about HPV infection and HPV vaccination using val-
idated instruments.23,34 Given that HPV vaccination is an insured
service and that the Colombian Ministry of Health is leading CC
prevention strategies,14 awareness of HPV vaccination in upcom-
ing studies could be compared to our results to explore persistence
of inequities.
Limitations of this study are primarily due to its cross-sectional
design, which only provides information about associations. In
addition, our study evaluated whether women had heard about
HPV and a vaccine to prevent CC, which could be considered as a
proxy of HPV vaccination awareness. Also, it needs to be acknowl-
edged that social desirability could have an impact on the ﬁndings.
In conclusion, almost three quarters of the women in Colom-
bia had not heard about HPV vaccination. The socio-demographic
variations found on having heard about HPV vaccination indicate
the presence of inequities and a social gradient in the awareness
of HPV vaccination in Colombia. These ﬁndings suggest that pro-
grams raising awareness of vaccination to prevent CC have had a
poor impact and that they could be neglecting marginalized groups
of women  in Colombia. Hence, further educational programs about
CC prevention and HPV vaccination should target the general pop-
ulation, although speciﬁc strategies are also necessary to reach
disadvantaged groups (low socioeconomic strata, individuals with
subsidized health insurance, women with no education, and those
living in isolated or rural regions).
What is known about the subject?
Cervical cancer (CC) is the most frequent cancer affecting
women in Colombia. A lack of awareness of HPV vaccina-
tion, critical for vaccination uptake and CC prevention, has
been described among disadvantaged groups. There are no
nationwide studies about socioeconomic factors associated
with awareness of HPV vaccination among Colombian women.
What does this study add to the literature?
Our nationwide results show the presence of inequities
and a social gradient on having heard about HPV vaccination
among women in Colombia, identifying a key role of educa-
tion and rural residence on HPV awareness. HPV vaccination
programs should include speciﬁc strategies to reach women
with low socioeconomic status, subsidized health insurance,
no insurance, no education, low education, and those living in
isolated and rural areas.
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